SG11202112052VA - Compositions and methods for treating presbyopia - Google Patents
Compositions and methods for treating presbyopiaInfo
- Publication number
- SG11202112052VA SG11202112052VA SG11202112052VA SG11202112052VA SG11202112052VA SG 11202112052V A SG11202112052V A SG 11202112052VA SG 11202112052V A SG11202112052V A SG 11202112052VA SG 11202112052V A SG11202112052V A SG 11202112052VA SG 11202112052V A SG11202112052V A SG 11202112052VA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- treating presbyopia
- presbyopia
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962849728P | 2019-05-17 | 2019-05-17 | |
| US16/590,830 US11071724B2 (en) | 2019-05-17 | 2019-10-02 | Compositions and methods for treating presbyopia |
| PCT/US2020/042414 WO2020237248A1 (en) | 2019-05-17 | 2020-07-16 | Compositions and methods for treating presbyopia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202112052VA true SG11202112052VA (en) | 2021-12-30 |
Family
ID=73230974
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202112052VA SG11202112052VA (en) | 2019-05-17 | 2020-07-16 | Compositions and methods for treating presbyopia |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11071724B2 (en) |
| EP (1) | EP3968839A1 (en) |
| JP (1) | JP2022539946A (en) |
| AU (1) | AU2020277504A1 (en) |
| CA (1) | CA3139130A1 (en) |
| GB (1) | GB2597411A (en) |
| MX (1) | MX2021013930A (en) |
| SG (1) | SG11202112052VA (en) |
| WO (1) | WO2020237248A1 (en) |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811446A (en) | 1997-04-18 | 1998-09-22 | Cytos Pharmaceuticals Llc | Prophylactic and therapeutic methods for ocular degenerative diseases and inflammations and histidine compositions therefor |
| US7799337B2 (en) | 1997-07-21 | 2010-09-21 | Levin Bruce H | Method for directed intranasal administration of a composition |
| US6372254B1 (en) | 1998-04-02 | 2002-04-16 | Impax Pharmaceuticals Inc. | Press coated, pulsatile drug delivery system suitable for oral administration |
| US6716830B2 (en) | 1998-09-30 | 2004-04-06 | Alcon, Inc. | Ophthalmic antibiotic compositions containing moxifloxacin |
| US6740664B2 (en) | 1998-09-30 | 2004-05-25 | Alcon, Inc. | Methods for treating otic and ophthalmic infections |
| DE19937116A1 (en) | 1999-08-06 | 2001-02-08 | Bayer Ag | Moxifloxacin saline formulation |
| PE20020146A1 (en) | 2000-07-13 | 2002-03-31 | Upjohn Co | OPHTHALMIC FORMULATION INCLUDING A CYCLOOXYGENASE-2 (COX-2) INHIBITOR |
| JP3450805B2 (en) | 2000-08-08 | 2003-09-29 | わかもと製薬株式会社 | Aqueous pharmaceutical composition |
| PE20020578A1 (en) | 2000-10-10 | 2002-08-14 | Upjohn Co | A TOPICAL ANTIBIOTIC COMPOSITION FOR THE TREATMENT OF EYE INFECTIONS |
| DE10158037A1 (en) | 2001-11-27 | 2003-07-03 | Kosmas Kg | Antiglaucomatous agent and its use |
| CN1684701B (en) | 2002-07-30 | 2012-10-17 | 奥默罗斯公司 | Ophthalmologic irrigation solutions and method |
| US7985422B2 (en) | 2002-08-05 | 2011-07-26 | Torrent Pharmaceuticals Limited | Dosage form |
| US8268352B2 (en) | 2002-08-05 | 2012-09-18 | Torrent Pharmaceuticals Limited | Modified release composition for highly soluble drugs |
| US20050261641A1 (en) | 2002-09-26 | 2005-11-24 | Warchol Mark P | Method for ophthalmic administration of medicament |
| US20070211212A1 (en) | 2002-09-26 | 2007-09-13 | Percy Bennwik | Eye state sensor |
| US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
| US8372814B2 (en) | 2004-06-07 | 2013-02-12 | Ista Pharmaceuticals, Inc. | Ophthalmic formulations and uses thereof |
| US7971070B2 (en) | 2005-01-11 | 2011-06-28 | International Business Machines Corporation | Read/write media key block |
| MX2007010025A (en) | 2007-08-17 | 2009-02-25 | Arturo Jimenez Bayardo | Pharmaceutical composition for treatment of ocular hypertension. |
| MX2007011165A (en) | 2007-09-12 | 2009-03-11 | Arturo Jimenez Bayardo | Pharmaceutically stable compound consisting of timolol, dorzolamide and brimonidine. |
| EP2666510B1 (en) | 2007-12-20 | 2017-10-18 | University Of Southern California | Apparatus for controlled delivery of therapeutic agents |
| ITRM20080182A1 (en) | 2008-04-07 | 2009-10-08 | Medivis S R L | OPHTHALMIC PREPARATION BASED ON DORZOLAMIDE AND LATANOPROST FOR THE TOP TREATMENT OF GLAUCOMA. |
| MX2008014515A (en) | 2008-09-09 | 2010-04-29 | Allergan Inc | Ophthalmic suspension for ocular use. |
| US20100105643A1 (en) | 2008-10-27 | 2010-04-29 | Soll David B | Ophthalmic composition |
| US8778999B2 (en) | 2009-03-05 | 2014-07-15 | Insite Vision Incorporated | Non-steroidal anti-inflammatory ophthalmic compositions |
| US9458536B2 (en) | 2009-07-02 | 2016-10-04 | Sio2 Medical Products, Inc. | PECVD coating methods for capped syringes, cartridges and other articles |
| PT3708178T (en) | 2009-08-24 | 2023-11-16 | Stealth Biotherapeutics Inc | Methods and compositions for preventing or treating ophthalmic conditions |
| CA2773597A1 (en) | 2009-09-17 | 2011-03-24 | Senju Pharmaceutical Co., Ltd. | Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
| US20110178147A1 (en) | 2009-10-20 | 2011-07-21 | Allergan, Inc. | Compositions and methods for controlling pupil dilation |
| BR112012010026B8 (en) | 2009-10-30 | 2021-02-02 | Aton Pharma Inc | method of forming an ocular release device and ocular release device |
| ES2787254T3 (en) | 2010-07-15 | 2020-10-15 | Eyenovia Inc | Supply of ophthalmic drugs |
| EP2462921A1 (en) | 2010-11-11 | 2012-06-13 | Novaliq GmbH | Liquid pharmaceutical compositions for the treatment of a posterior eye disease |
| US20130020227A1 (en) | 2011-07-20 | 2013-01-24 | Pharma Vision, LLC | Post-operative cataract kit and method |
| US20130035338A1 (en) | 2011-08-05 | 2013-02-07 | Gordon Tang | Eyelid treatment |
| US9554968B2 (en) | 2013-03-11 | 2017-01-31 | Sio2 Medical Products, Inc. | Trilayer coated pharmaceutical packaging |
| US20130165419A1 (en) | 2011-12-21 | 2013-06-27 | Insite Vision Incorporated | Combination anti-inflammatory ophthalmic compositions |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US9827250B2 (en) | 2012-07-31 | 2017-11-28 | Johnson & Johnson Vision Care, Inc. | Lens incorporating myopia control optics and muscarinic agents |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Surgical (Ireland) Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| EP2961858B1 (en) | 2013-03-01 | 2022-09-07 | Si02 Medical Products, Inc. | Coated syringe. |
| US20160175323A1 (en) | 2013-07-22 | 2016-06-23 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20160243031A1 (en) | 2013-07-22 | 2016-08-25 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
| US20150025511A1 (en) | 2013-07-22 | 2015-01-22 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20150164882A1 (en) | 2013-07-22 | 2015-06-18 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20160279055A1 (en) | 2013-07-22 | 2016-09-29 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| US20160101118A1 (en) | 2014-08-15 | 2016-04-14 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| MX2016000964A (en) | 2013-07-22 | 2016-08-03 | Imprimis Pharmaceuticals Inc | Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an antiinflammatory agent. |
| US20150129457A1 (en) | 2013-07-22 | 2015-05-14 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| US20190105320A1 (en) | 2013-07-22 | 2019-04-11 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions for intraocular administration and methods for fabricating thereof |
| MX2016004257A (en) | 2013-10-03 | 2016-08-17 | Imprimis Pharmaceuticals Inc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof. |
| US20150335704A1 (en) | 2014-05-23 | 2015-11-26 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical compositions comprising gels and methods for fabricating thereof |
| JP2018521000A (en) | 2015-05-29 | 2018-08-02 | シドネキシス，インク． | Pharmaceutical formulation stabilized with D2O |
| CH711969A2 (en) | 2015-12-29 | 2017-06-30 | Pinelli Roberto | Composition for the treatment of presbyopia. |
| US20190111045A1 (en) | 2016-05-06 | 2019-04-18 | Harrow Health, Inc. | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
| KR20190109604A (en) | 2016-05-06 | 2019-09-25 | 해로우 헬스 인코포레이티드 | Pharmaceutical ophthalmic compositions and methods for fabricating thereof |
| CA3034640A1 (en) | 2016-08-25 | 2018-03-01 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
-
2019
- 2019-10-02 US US16/590,830 patent/US11071724B2/en active Active
-
2020
- 2020-07-16 AU AU2020277504A patent/AU2020277504A1/en active Pending
- 2020-07-16 CA CA3139130A patent/CA3139130A1/en not_active Abandoned
- 2020-07-16 WO PCT/US2020/042414 patent/WO2020237248A1/en active Application Filing
- 2020-07-16 EP EP20808746.0A patent/EP3968839A1/en not_active Withdrawn
- 2020-07-16 MX MX2021013930A patent/MX2021013930A/en unknown
- 2020-07-16 GB GB2116011.4A patent/GB2597411A/en not_active Withdrawn
- 2020-07-16 SG SG11202112052VA patent/SG11202112052VA/en unknown
- 2020-07-16 JP JP2021567892A patent/JP2022539946A/en active Pending
-
2021
- 2021-06-09 US US17/343,125 patent/US20210361625A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210361625A1 (en) | 2021-11-25 |
| US11071724B2 (en) | 2021-07-27 |
| JP2022539946A (en) | 2022-09-14 |
| GB2597411A (en) | 2022-01-26 |
| AU2020277504A1 (en) | 2021-12-23 |
| US20200360346A1 (en) | 2020-11-19 |
| EP3968839A1 (en) | 2022-03-23 |
| MX2021013930A (en) | 2022-01-26 |
| WO2020237248A1 (en) | 2020-11-26 |
| WO2020237248A8 (en) | 2021-12-02 |
| CA3139130A1 (en) | 2020-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202006627B (en) | Methods and compositions for treating cancer | |
| GB2578539B (en) | Compositions and methods for preventing or treating muscle conditions | |
| IL288914A (en) | Compositions and methods for treating cancer | |
| IL286350A (en) | Compositions and methods for treating cancer | |
| ZA202207394B (en) | Compositions and methods for treating hemoglobinopathies | |
| IL285886A (en) | Compositions and methods for treating laminopathies | |
| IL289970A (en) | Compositions and methods for treating autoimmune disorders | |
| IL271256A (en) | Compositions and methods for treating tauopathies | |
| ZA202101362B (en) | Compositions and methods for treating the eye | |
| SG11202103033WA (en) | Compositions and methods for the treatment of presbyopia | |
| IL280413A (en) | Bismuth-thiol compositions and methods for treating wounds | |
| ZA202104870B (en) | Methods and compositions for treating cancer | |
| EP3687524A4 (en) | Compositions and methods for treating ophthalmic conditions | |
| SG11202012055PA (en) | Methods and compositions for preventing or treating calciphylaxis | |
| EP3833340A4 (en) | Compositions and methods for treatment of presbyopia | |
| SG11202012435UA (en) | Compositions and methods for treating cancer | |
| IL287982A (en) | Compositions and methods for treating cancer | |
| ZA202101342B (en) | Compositions and methods for treating the eye | |
| IL277779A (en) | Compositions and methods for treating macular dystrophy | |
| SG11202011151VA (en) | Compositions and methods for reducing spliceopathy and treating rna dominance disorders | |
| IL287831A (en) | Oxymetazoline compositions and methods for treating ocular disorders | |
| IL277463A (en) | Compositions and methods for treating pruritus | |
| IL285796A (en) | Methods and compositions for treating | |
| IL288440A (en) | Compositions and methods for treating retinopathy | |
| IL286153A (en) | Methods and compositions for treating cancer |